Coronary Artery Disease News and Research

Latest Coronary Artery Disease News and Research

Study: High concentrations of cocoa flavanols decrease blood pressure

A new study by UCSF cardiologists and researchers found that high concentrations of cocoa flavanols decrease blood pressure, improve the health of blood vessels and increase the number of circulating blood-vessel-forming cells in patients with heart disease. The findings indicate that foods rich in flavanols - such as cocoa products, tea, wine, and various fruits and vegetables - have a cardio-protective benefit for heart disease patients.

7 Jul 2010

Cambridge Heart commences enrollment in study to identify ischemia in patients with coronary artery disease

Cambridge Heart, Inc., today announced the first patient enrollments in the MTWA-CAD study (Evaluation of Microvolt T-Wave Alternans Testing for the Detection of Active Ischemia in Patients with Known or Suspected Coronary Artery Disease).

7 Jul 2010

Shire receives FDA approval of Daytrana for ADHD in adolescents

Shire plc, the global specialty biopharmaceutical company, announced the US Food and Drug Administration (FDA) approval of Daytrana® (methylphenidate transdermal system) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents aged 13 to 17 years. Daytrana, the first and only transdermal ADHD patch, is already an FDA-approved ADHD treatment for children 6 to 12 years. Daytrana is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational, and social).

7 Jul 2010

Researchers report no increased rate of heart attack in patients taking rosiglitazone

The diabetes drug rosiglitazone has been under intense scrutiny since a 2007 study in the New England Journal of Medicine looked at more than 40 clinical trials and linked the drug's use with increased risk of heart attack and death from heart disease.

1 Jul 2010

Lack of reimbursements limit drug-eluting stent market across Latin America

According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, despite the rising popularity of drug-eluting stents (DES) across Latin America, bare-metal stents (BMS) will continue to represent a significant portion of the overall coronary stent market through 2014. This trend is especially evident in Brazil, where the public healthcare system does not provide any reimbursement for DES procedures.

30 Jun 2010

Gastric bypass surgery can help improve ratio of total cholesterol to HDL cholesterol: Study

Gastric bypass surgery can help lower cholesterol and improve the ratio of total cholesterol to HDL (good) cholesterol, according to a new study presented here at the 27th Annual Meeting of the American Society for Metabolic & Bariatric Surgery.

28 Jun 2010

ADVANCE study provides new insights into the management of SHPT in CKD patients

Results from the ADVANCE study presented in a late breaking clinical trial session at the ERA-EDTA 2010 Congress provide new insights into the management of secondary hyperparathyroidism in chronic kidney disease patients. ADVANCE (A randomiseD VAscular calcificatioN study to evaluate the effects of CinacalcEt) is a randomised, controlled open label study to evaluate the effects of treatment with Mimpara (cinacalcet) plus low-dose vitamin D, compared to flexible doses of vitamin D alone, on the progression of vascular and valvular calcification in dialysis patients with SHPT.

28 Jun 2010

New affiliation formed to accelerate nation's progress in fighting HIV/AIDS

Two leading institutions in public health and health policy are joining forces to accelerate the nation's progress in fighting HIV/AIDS, hepatitis C and tuberculosis in Washington – the Forum for Collaborative HIV Research and the University of California, Berkeley, School of Public Health.

28 Jun 2010

Two experimental drugs have potential to restore pumping strength to failing hearts, study finds

We've all experienced the strong heartbeat that accompanies emotions such as fear and rage. But can the body's natural response to these emotions be used to combat heart failure? Results of a study published online today in the journal Circulation Research present a strong case.

25 Jun 2010

Tryton announces first three implants of Side Branch Stent System in Israel

Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, announced that the company's TRYTON Side Branch Stent™ System has been used in three cases in Israel for the first time.

24 Jun 2010

Anthera commences enrollment in pivotal VISTA-16 Phase 3 clinical study of varespladib

Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced patient enrollment has commenced in the Company's pivotal VISTA-16 (Vascular Inflammation Suppression to Treat Acute Coronary Syndrome for 16 Weeks) Phase 3 clinical study of varespladib (A-002).

23 Jun 2010

Corgenix receives new European patent for AtherOx technology

Corgenix Medical Corporation, a worldwide developer and marketer of diagnostic test kits, announced today the issuance of one new European patent for the company's AtherOx® (oxLDL/B2GPI) technology and the publication of an important clinical trial studying oxLDL/B2GPI levels in patients with acute coronary syndrome (ACS).

23 Jun 2010

Exercise alone without creatine supplements helps in cardiac rehabilitation

Athletes have been enjoying the benefits of creatine supplements to gain stronger muscles since the 1990s, and the supplement has also proven beneficial among other groups. Could it help cardiac patients regain strength to help with their heart-training workouts as part of rehabilitation? The evidence at this stage suggests not - exercise alone proved a far more powerful tonic for patients in a study out today. The results appear in the journal Clinical Rehabilitation, published by SAGE.

23 Jun 2010

Cell>Point submits IND application for Phase 1b/2 99mTc-EC-G diagnostic trial in assessing CAD patients

Cell>Point announced today that it has submitted to the Food and Drug Administration an Investigational New Drug (IND) application for a Phase 1b/2 trial of its 99mTc-EC-G diagnostic in assessing patients with Coronary Artery Disease (CAD).

23 Jun 2010

Cardiogenesis' shares quoted on newly launched OTCQB market

Cardiogenesis Corporation today announced that its shares are now being quoted on the newly launched OTCQB market. Launched in April 2010, the OTCQB is a new market tier for OTC-traded U.S. companies that are registered and reporting with the Securities and Exchange Commission.

22 Jun 2010

LIVALO for primary hyperlipidemia or mixed dyslipidemia now available in U.S.

Kowa Pharmaceuticals America, Inc., and Eli Lilly and Company today announced that LIVALO® (pitavastatin) tablets is now available in retail pharmacies throughout the United States. LIVALO, a statin medication approved by the U.S. Food and Drug Administration (FDA) in August 2009 is indicated for adults as an adjunctive therapy to diet for the treatment of primary hyperlipidemia or mixed dyslipidemia. LIVALO is available in doses of 1 mg, 2 mg and 4 mg.

21 Jun 2010

Most men admitted for heart attack had erectile dysfunction

Seven out of 10 men admitted to hospital for a heart attack (acute ST segment elevation myocardial infarction (STEMI)) had erectile dysfunction (ED) in the six months prior to their admission according to new data presented today at the World Congress of Cardiology (WCC) Scientific Sessions in Beijing, China.

19 Jun 2010

Research may identify reasons underlying increased risk of AAA in men

Research currently being undertaken at the University of Leicester may identify reasons underlying an increased risk of Abdominal Aortic Aneurysms in men.

19 Jun 2010

Women receive greater clinical benefit from CRT-Ds than men: Study

Boston Scientific Corporation today announced results from a sub-analysis of the MADIT-CRT trial data that showed women received a greater clinical benefit from its cardiac resynchronization therapy defibrillators (CRT-Ds) than men. The results were presented during the 17th Cardiostim World Congress by Jonathan Steinberg, M.D., Chief of Cardiology and Director of the Al-Sabah Arrythmia Institute, St. Luke's-Roosevelt Hospital Center, New York.

18 Jun 2010

InfraReDx to demonstrate LipiScan coronary imaging system during CCC Symposium

InfraReDx, Inc., an innovative medical device company focused on developing novel diagnostic imaging technologies to accurately identify and characterize diseased tissues, today announced that its LipiScan Coronary Imaging System will be featured at the 13th Annual Live Symposium of Complex Coronary & Vascular Cases being held at The Mount Sinai Medical Center of New York, from June 16-19, 2010.

16 Jun 2010